MannKind Corp at JPMorgan Healthcare Conference Transcript
Hello, all. Welcome. My name is [Tousy Kuwash], and I'm an associate at JPMorgan. It's my pleasure to welcome our speaker for today, Michael Castagna, CEO of MannKind.
And with that, I'll hand over to Michael to get started.
Thank you for having us today. I appreciate being back at JPMorgan. It's been a great week and a great conference, and thank you for hosting it this year.
So MannKind, as you saw, is really about paving the future of orphan lung diseases and how we have pivoted the company from what we were known as 31 years of an inhalation diabetes company that was struggling to now really pivoting to a pipeline that has multiple shots on goal, nebulized and dry powders, along with a nice royalty stream with our partnership with United Therapeutics to a diabetes franchise that is growing and has lots of good readouts in the next year.
Our mission is really to give people control of their health and the freedom to live life. As we sit back and looked
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
